CNS-5161
CNS-5161 is an NMDA receptor antagonist which was under development for the treatment of neuropathic pain and cancer pain but was never marketed.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
CNS-5161 is an NMDA receptor antagonist which was under development for the treatment of neuropathic pain and cancer pain but was never marketed. It is taken by intravenously or transdermally. CNS-5161 was under development by CeNeS Pharmaceuticals. It reached phase 2 trials prior to the discontinuation of its development.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1376787595 under CC BY-SA 4.0; modifications have been made.